Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)

Next Previous
X
Search
Trial Profile

A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emprumapimod (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Registrational; Therapeutic Use
  • Acronyms REALM-DCM
  • Sponsors Array BioPharma; Pfizer

    • Most Recent Events

    • 01 Jul 2024 Primary endpoint (Change From Baseline in Six-Minute Walk Test (6 MWT) at Week 24) has not been met, according to Results published in the Circulation: Heart Failure.
    • 01 Jul 2024 Results published in the Circulation: Heart Failure
    • 04 Feb 2024 This trial has been discontinued in Italy according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top